Latest Observability News

Rubix Resources has reported assay results from its Queensland Paperbark Project that align with expectations, revealing significant zinc, lead, and copper mineralisation. The company also advances exploration across multiple projects and pursues new asset acquisitions.

Audio Pixels Holdings has locked in a $6 million unsecured loan facility from an investor linked to its chairman, with conversion to notes contingent on shareholder approval and company milestones.

Provaris Energy has made significant strides in hydrogen and liquid carbon dioxide storage technologies, reinforcing key partnerships and securing funding to meet critical 2026 milestones.

I Synergy Group Limited has taken a significant step in its AI infrastructure ambitions by leasing its high-performance computing assets and AI software to four third parties, setting the stage for new revenue streams and strategic growth.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

Estrella Resources has reported multiple high-grade manganese intersections at its Ira Miri project, including assays up to 58% manganese, and received regulatory approval for a 30,000-tonne bulk sample extraction. Concurrently, drilling at the Werumata limestone project has been completed with assay results pending.

Power Minerals has commenced a significant 10,000m reverse circulation drilling program at its Santa Anna Project in Brazil, aiming to expand and deepen the footprint of high-grade niobium and rare earth elements mineralisation. Results are anticipated by late March 2026.

MRG Metals has expanded its rare earth portfolio through the acquisition of the high-grade Garies Rare Earth Project in South Africa, while also progressing key projects in Mozambique, signalling a diversified growth strategy in critical minerals.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

Fleetwood Limited has appointed Andrea Pidcock as its new CEO, bringing a wealth of operational and commercial leadership experience to the industrial and construction services company. Her appointment signals a strategic push towards operational excellence and growth through modern construction methods.

Battery Age Minerals has completed maiden drilling programs in Austria and Argentina, secured full ownership of its Canadian lithium project, and raised A$5.5 million to fuel its 2026 exploration ambitions.